4 hours KalVista Pharmaceuticals (NASDAQ:KALV) Rating Reiterated by HC Wainwright MarketBeat
HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday.
Nasdaq 100 · Pharmaceuticals · Science